These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26729694)

  • 1. Medical treatment for chronic aortic regurgitation: β-blockers--maybe not bad, but good?
    Evangelista A
    Heart; 2016 Feb; 102(3):168-9. PubMed ID: 26729694
    [No Abstract]   [Full Text] [Related]  

  • 2. Heartbeat: Beta-blockers for aortic regurgitation.
    Otto CM
    Heart; 2016 Feb; 102(3):165-7. PubMed ID: 26769375
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled release metoprolol for aortic regurgitation: a randomised clinical trial.
    Broch K; Urheim S; Lønnebakken MT; Stueflotten W; Massey R; Fosså K; Hopp E; Aakhus S; Gullestad L
    Heart; 2016 Feb; 102(3):191-7. PubMed ID: 26661319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of losartan and metoprolol on left ventricular and aortic function at rest and during exercise in chronic aortic regurgitation.
    Roberts PA; Lin ACW; Cowan BR; Young AA; Stewart R
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):615-624. PubMed ID: 29119275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of beta-blockade in experimental chronic aortic regurgitation.
    Plante E; Lachance D; Gaudreau M; Drolet MC; Roussel E; Arsenault M; Couet J
    Circulation; 2004 Sep; 110(11):1477-83. PubMed ID: 15353507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
    Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation.
    Zendaoui A; Lachance D; Roussel E; Couet J; Arsenault M
    Circ Heart Fail; 2011 Mar; 4(2):207-13. PubMed ID: 21216836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Block the ischemia and reperfusion damage: an old adjunctive drug for a new reperfusion strategy.
    Antoniucci D
    J Am Coll Cardiol; 2014 Jun; 63(22):2363-4. PubMed ID: 24694532
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure.
    Pasternak B; Mattsson A; Svanström H; Hviid A
    Int J Cardiol; 2015; 190():4-6. PubMed ID: 25912106
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of coronary flow reserve and left ventricular remodeling in a mouse model of chronic aortic regurgitation with carvedilol intervention.
    Wang X; Wu J; Zhu D; You J; Zou Y; Qian J; Ge J
    J Ultrasound Med; 2015 Mar; 34(3):483-93. PubMed ID: 25715369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers in the treatment of aortic regurgitation a new opportunity?
    Elkayam U
    J Am Coll Cardiol; 2009 Jul; 54(5):458-9. PubMed ID: 19628122
    [No Abstract]   [Full Text] [Related]  

  • 13. β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial.
    Silvestre OM; Farias AQ; Ramos DS; Furtado MS; Rodrigues AC; Ximenes RO; de Campos Mazo DF; Yoshimura Zitelli PM; Diniz MA; Andrade JL; Strunz C; Friedmann AA; Lee SS; Carrilho FJ; D'Albuquerque LAC; Bacal F
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):930-937. PubMed ID: 29979644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
    Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
    Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivabradine in Cardiovascular Disease: Heart Rate Isn't Everything.
    Feldman AM
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):549-51. PubMed ID: 25714600
    [No Abstract]   [Full Text] [Related]  

  • 16. Early intravenous beta-blockade before primary percutaneous coronary intervention gives major benefits, apparently without side effects.
    Opie LH
    J Am Coll Cardiol; 2014 Oct; 64(17):1864. PubMed ID: 25443713
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Ivabradine on Heart Rate and Duration of Exercise in Patients With Mild-to-Moderate Mitral Stenosis: A Randomized Comparison With Metoprolol.
    Saggu DK; Narain VS; Dwivedi SK; Sethi R; Chandra S; Puri A; Saran RK
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):552-4. PubMed ID: 25636072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply: early intravenous beta-blockade before primary percutaneous coronary intervention gives major benefits apparently without side effects.
    Ibanez B; Fuster V
    J Am Coll Cardiol; 2014 Oct; 64(17):1864-5. PubMed ID: 25443712
    [No Abstract]   [Full Text] [Related]  

  • 19. Chirally pure S-metoprolol--place in therapy.
    Dasbiswas A; Dasbiswas D
    Indian Heart J; 2010; 62(2):143-5. PubMed ID: 21180306
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute and short-term hemodynamic effects of metoprolol in Eisenmenger syndrome: a preliminary observational study.
    Ramakrishnan S; Vyas C; Kothari SS; Bhargava B; Kukreti BB; Kalaivani M; Juneja R; Seth S; Saxena A; Bahl VK
    Am Heart J; 2011 May; 161(5):938-43. PubMed ID: 21570526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.